Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 9/20 | 0.52 |
| ▸ | AVPR1A | P37288 | 9/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978877 | 0.87 | AVPR2 (0.50) | AVPR2AVPR1AMAPTTP53LMNA | |
| SCHEMBL4509703 | 0.86 | AVPR2 (0.60) | AVPR2AVPR1AMAPTTP53 | |
| SCHEMBL3979687 | 0.86 | AVPR2 (0.60) | AVPR2AVPR1AMAPTTP53P2RX3 | |
| SCHEMBL3983031 | 0.85 | AVPR2 (0.59) | AVPR2AVPR1AMAPTTP53 | |
| SCHEMBL4491301 | 0.85 | AVPR2 (0.53) | AVPR2AVPR1AMAPTTP53LMNA | |
| SCHEMBL8233213 | 0.85 | AVPR2 (0.60) | AVPR2AVPR1AMAPTTP53 | |
| SCHEMBL8233642 | 0.84 | AVPR2 (0.60) | AVPR2AVPR1AMAPTTP53P2RX3 | |
| SCHEMBL3977873 | 0.84 | AVPR2 (0.60) | AVPR2AVPR1AMAPTTP53 | |
| SCHEMBL4504170 | 0.84 | AVPR2 (0.57) | AVPR2AVPR1AMAPTTP53 | |
| SCHEMBL3986162 | 0.83 | AVPR2 (0.61) | AVPR2AVPR1AMAPTTP53P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885AVPR1A 2/4885MAPT 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.